Verona Pharma (LON:VRP)‘s stock had its “buy” rating reissued by analysts at Shore Capital in a research report issued to clients and investors on Tuesday.
Separately, Jefferies Financial Group restated a “buy” rating on shares of Verona Pharma in a research report on Tuesday, August 7th.
Shares of LON VRP opened at GBX 117.50 ($1.54) on Tuesday. Verona Pharma has a 12-month low of GBX 100 ($1.31) and a 12-month high of GBX 189 ($2.47).
Verona Pharma Company Profile
Verona Pharma plc, a clinical stage biopharmaceutical company, develops and commercializes therapeutics to treat respiratory diseases. The company's product candidate is RPL554, an inhaled dual inhibitor of the enzymes phosphodiesterase 3 and 4, which has completed Phase I and IIa clinical trials that acts as a bronchodilator and an anti-inflammatory agent for the treatment of chronic obstructive pulmonary disease and cystic fibrosis.
Read More: What is the Ex-Dividend Date in Investing?
Receive News & Ratings for Verona Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Verona Pharma and related companies with MarketBeat.com's FREE daily email newsletter.